Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2011, Article ID 742020, 6 pages
http://dx.doi.org/10.1155/2011/742020
Clinical Study

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan

Received 25 January 2011; Revised 12 April 2011; Accepted 14 April 2011

Academic Editor: Rupert M. Menapace

Copyright © 2011 Wataru Matsumiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Hernandez-Pastor, A. Ortega, A. Garcia-Layana, and J. Giraldez, “Ranibizumab for neovascular age-related macular degeneration,” American Journal of Health-System Pharmacy, vol. 65, no. 19, pp. 1805–1814, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Morris, F. Imrie, A. M. Armbrecht, and B. Dhillon, “Age-related macular degeneration and recent developments: new hope for old eyes?” Postgraduate Medical Journal, vol. 83, no. 979, pp. 301–307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Mitchell, J. F. Korobelnik, P. Lanzetta et al., “Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials,” British Journal of Ophthalmology, vol. 94, no. 1, pp. 2–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. E. Fung, G. A. Lalwani, P. J. Rosenfeld et al., “An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,” American Journal of Ophthalmology, vol. 143, no. 4, pp. 566–583.e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Suzuki, F. Gomi, M. Sawa, M. Tsujikawa, and H. Sakaguchi, “Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in japanese patients,” Japanese Journal of Ophthalmology, vol. 54, no. 2, pp. 124–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Maruko, T. Iida, M. Saito, D. Nagayama, and K. Saito, “Clinical characteristics of exudative age-related macular degeneration in Japanese patients,” American Journal of Ophthalmology, vol. 144, no. 1, pp. 15–22.e2, 2007. View at Publisher · View at Google Scholar
  7. A. Tsujikawa, S. Ooto, K. Yamashiro, H. Tamura, A. Otani, and N. Yoshimura, “Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab,” Japanese Journal of Ophthalmology, vol. 54, no. 4, pp. 310–319, 2010. View at Publisher · View at Google Scholar
  8. F. Gomi, M. Sawa, H. Sakaguchi et al., “Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy,” British Journal of Ophthalmology, vol. 92, no. 1, pp. 70–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. N. Stangos, J. S. Gandhi, J. Nair-Sahni, H. Heimann, C. J. Pournaras, and S. P. Harding, “Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab,” American Journal of Ophthalmology, vol. 150, no. 5, pp. 666–673, 2010. View at Publisher · View at Google Scholar
  10. L. A. Yannuzzi, J. Sorenson, R. F. Spaide, and B. Lipson, “Idiopathic polypoidal choroidal vasculopathy (IPCV),” Retina, vol. 10, no. 1, pp. 1–8, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. L. A. Yannuzzi, A. Ciardella, R. F. Spaide, M. Rabb, K. Bailey Freund, and D. A. Orlock, “The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy,” Archives of Ophthalmology, vol. 115, no. 4, pp. 478–485, 1997. View at Google Scholar · View at Scopus
  12. M. Uyama, T. Matsubara, I. Fukushima et al., “Idiopathic polypoidal choroidal vasculopathy in Japanese patients,” Archives of Ophthalmology, vol. 117, no. 8, pp. 1035–1042, 1999. View at Google Scholar · View at Scopus
  13. R. F. Spaide, L. A. Yannuzzi, J. S. Slakter, J. Sorenson, and D. A. Orlach, “Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy,” Retina, vol. 15, no. 2, pp. 100–110, 1995. View at Google Scholar
  14. A. P. Ciardella, I. M. Donsoff, S. J. Huang, D. L. Costa, and L. A. Yannuzzi, “Polypoidal choroidal vasculopathy,” Survey of Ophthalmology, vol. 49, no. 1, pp. 25–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. U. M. Schmidt-Erfurth, G. Richard, A. Augustin et al., “Guidance for the treatment of neovascular age-related macular degeneration,” Acta Ophthalmologica Scandinavica, vol. 85, no. 5, pp. 486–494, 2007. View at Publisher · View at Google Scholar
  16. M. S. Ip, I. U. Scott, G. C. Brown et al., “Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology,” Ophthalmology, vol. 115, no. 10, pp. 1837–1846, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Y. Y. Lai, W. M. Chan, D. T. L. Liu, and D. S. C. Lam, “Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia,” Retina, vol. 29, no. 6, pp. 750–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Konstantinidis, I. Mantel, J. A. C. Pournaras, L. Zografos, and A. Ambresin, “Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 3, pp. 311–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. M. Carneiro, R. M. Silva, M. J. Veludo et al., “Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia,” Ophthalmologica, vol. 225, no. 2, pp. 81–88, 2011. View at Publisher · View at Google Scholar
  20. G. Mimoun, J. Tilleul, A. Leys, G. Coscas, G. Soubrane, and E. H. Souied, “Intravitreal ranibizumab for choroidal neovascularization in angioid streaks,” American Journal of Ophthalmology, vol. 150, no. 5, pp. 692–700.e1, 2010. View at Publisher · View at Google Scholar
  21. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar
  22. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study,” Ophthalmology, vol. 116, no. 1, pp. 57–65.e5, 2009. View at Publisher · View at Google Scholar
  23. P. J. Mekjavic, A. Kraut, M. Urbancic, E. Lenassi, and M. Hawlina, “Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections,” Acta Ophthalmologica. In press.
  24. F. Gomi, M. Ohji, K. Sayanagi et al., “One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients,” Ophthalmology, vol. 115, no. 1, pp. 141–146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Honda, Y. Kurimoto, Y. Kagotani, H. Yamamoto, H. Takagi, and M. Uenishi, “Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan,” Japanese Journal of Ophthalmology, vol. 53, no. 6, pp. 593–597, 2009. View at Publisher · View at Google Scholar
  26. F. Wen, C. Chen, D. Wu, and H. Li, “Polypoidal choroidal vasculopathy in elderly Chinese patients,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 242, no. 8, pp. 625–629, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Y. Y. Lai, W. M. Chan, D. T. L. Liu, F. O. J. Luk, and D. S. C. Lam, “Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy,” British Journal of Ophthalmology, vol. 92, no. 5, pp. 661–666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. G. T. Kokame, L. Yeung, and J. C. Lai, “Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results,” British Journal of Ophthalmology, vol. 94, no. 3, pp. 297–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Reche-Frutos, C. Calvo-Gonzalez, J. Donate-Lopez, J. Garcia-Feijoo, M. Leila, and J. Garcia-Sanchez, “Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy,” European Journal of Ophthalmology, vol. 18, no. 4, pp. 645–648, 2008. View at Google Scholar · View at Scopus
  30. T. Hikichi, H. Ohtsuka, M. Higuchi et al., “Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months,” American Journal of Ophthalmology, vol. 150, no. 5, pp. 674–682.e1, 2010. View at Publisher · View at Google Scholar